Template:Dgfn2015 Mo 7:00 PCSK9
From HOP house of papers
(Difference between revisions)
Ossip Groth (Talk | contribs) m |
Ossip Groth (Talk | contribs) m |
||
| Line 1: | Line 1: | ||
| − | + | ==DGFN2015 Neue Wirkansätze in der Hyperlipidämie - Stellenwert für die Nephrologie (Rump-LC,Gouni-Berthold-I)== | |
| + | [http://nephrologie.conference2web.com/contentsessions/1945 Session Videos] | ||
===Lipidmanagement bei CKD-Patienten, Was ist belegt, was zu beachten. (Wanner-W)=== | ===Lipidmanagement bei CKD-Patienten, Was ist belegt, was zu beachten. (Wanner-W)=== | ||
Latest revision as of 19:06, 14 September 2015
Contents |
DGFN2015 Neue Wirkansätze in der Hyperlipidämie - Stellenwert für die Nephrologie (Rump-LC,Gouni-Berthold-I)
Lipidmanagement bei CKD-Patienten, Was ist belegt, was zu beachten. (Wanner-W)
| Journal Paper, restricted access |
| GET A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Extract PDF direct |
| Journal Paper, restricted access |
| GET Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates Extract PDF direct |
| Journal Paper, restricted access |
| GET The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Extract PDF direct |
| Journal Paper, restricted access |
| GET Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Extract PDF direct |
PCSK9-Inhibitoren: ein neuer Wirkmechanismus (Schettler-V)
| Journal Paper, restricted access |
| GET A century of cholesterol and coronaries: from plaques to genes to statins Extract PDF direct |
| Journal Paper, restricted access |
| GET Targeting PCSK9 for hypercholesterolemia Extract PDF direct |
| Journal Paper, restricted access |
| GET The biology and therapeutic targeting of the proprotein convertases Extract PDF direct |
| Journal article, free access |
| GET Plasma membrane CD81 complexes with PCSK9 and LDLR and its levels are reduced by PCSK9 Extract PDF direct |
| Journal Paper, restricted access |
| GET Protease variants, LDL, and coronary heart disease Extract PDF direct |
| Journal article, free access |
| GET Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia Extract PDF direct |
| Journal Paper, restricted access |
| GET Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Extract PDF direct |
| Journal Paper, restricted access |
| GET Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis Extract PDF direct |
| Journal article, free access |
| GET Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease Extract PDF direct |
| Journal article, free access |
| GET Sequence variations in PCSK9, low LDL, and protection against coronary heart disease Extract PDF direct |
| Journal article, free access |
| GET Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study Extract PDF direct |
| Journal article, free access |
| GET The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol Extract PDF direct |
| Journal article, free access |
| GET The PCSK9 decade Extract PDF direct |
| Journal Paper, restricted access |
| GET Antihyperlipidemic therapies targeting PCSK9 Extract PDF direct |
| Journal Paper, restricted access |
| GET Pharmacotherapies for lipid modification: beyond the statins Extract PDF direct |
| Journal article, free access |
| GET Lipids and CVD management: towards a global consensus Extract PDF direct |
| Journal article, free access |
| GET High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol Extract PDF direct |
| Journal Paper, restricted access |
| GET The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe Extract PDF direct |
| Journal article, free access |
| GET A 52-week placebo-controlled trial of evolocumab in hyperlipidemia Extract PDF direct |
| Journal Paper, restricted access |
| GET Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Extract PDF direct |
| Journal article, free access |
| GET AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial Extract PDF direct |
| Journal Paper, restricted access |
| GET Lipoprotein(a) mass: a massively misunderstood metric Extract PDF direct |
| Journal article, free access (Hinweis: wrong paper ??? 2015;15:41 Schettler) |
| GET Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels Extract PDF direct |
| Journal article, free access |
| GET Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis Extract PDF direct |
Was kommt nach den Statinen ? Aktuelles zu PCSK9 Antikörpern (König-W)
| Journal article, free access |
| GET Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials Extract PDF direct |
| Journal Paper, restricted access |
| GET Meta-analysis of comparative efficacy of increas.ing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Extract PDF direct |
| Journal Paper, restricted access |
| GET Efficacy and safety of evolocumab in reducing lipids and cardiovascular events Extract PDF direct |
